Table 4 Characteristics and severity for each of the five MG subtypes

Patients (n)

250

234

140

132

(22)

332

1088

Female,%

52.0

67.5

81.4*

81.1*

(81.8)

61.1

65.4

Onset age, y

51.0 ± 20.0, 53.0^a

51.0 ± 12.8, 51.0

33.3 ± 13.9, 31.0^a

39.9 ± 16.2, 41.5^a

(38.6 ± 15.3, 42.0)

50.7 ± 20.7, 55.0^a

47.3 ± 18.8, 48.1

Duration of disease, y

10.4 ± 11.4, 6.4

9.5 ± 7.7, 8.0

17.4 ± 11.8, 14.5^a

10.8 ± 9.3, 8.0

(11.0 ± 8.1, 9.8)

11.6 ± 10.5, 8.2

11.6 ± 10.6, 8.2

AChR-Ab-positivity,%

77.2

99.6

89.4

0.0

(0.0)

100.0

81.3

MuSK-Ab-positivity,%

0.0%

0.0%

0.0%

20.6%

(100.0%)

0.0%

2.1%

Thymectomy,%

23.6%*

97.4%*

100.0%*

12.1%*

(9.1%)

35.8%*

51.7%

 MGFA classification

 (n = 1088)

 I,%

100%

0.0%

0.0%

0.0%

(0.0%)

0.0%

23.0%

 II,%

0.0%

44.0%

52.9%

59.1%

(45.5%)

64.8%

43.2%

 III,%

0.0%

27.8%

30.7%

28.0%

(13.6%)

20.5%

19.6%

 IV,%

0.0%

7.7%

7.9%

4.5%

(9.1%)

4.2%

4.5%

 V,%

0.0%

20.5%

8.6%

8.3%

(31.8%)

10.5%

9.7%

 Rate of MGFA > III,%

0.0%*

56.0%*

47.1%

40.9%

(54.5%)

35.2%

33.8%

 QMG score

 (n = 922)

6.6 ± 2.6, 6.0^a

(n = 225)

17.1 ± 8.0,15.5^a

(n = 194)

15.8 ± 5.8, 15.0^a

(n = 107)

14.7 ± 7.2, 13.0

(n = 114)

18.1 ± 9.7, 15.5

(n = 20)

14.7 ± 7.0, 13.0

(n = 282)

13.4 ± 7.5, 12.0

 QMG score

 (n = 923)

4.2 ± 2.8, 4.0^a

(n = 208)

6.8 ± 4.8, 6.0

(n = 198)

7.8 ± 5.5, 7.0

(n = 125)

8.4 ± 5.4, 8.0

(n = 106)

(8.3 ± 6.4, 7.0)

(n = 20)

7.2 ± 4.8, 6.0

(n = 286)

6.6 ± 4.8, 6.0

 MGC score

 (n = 923)

1.9 ± 2.5, 1.0^a

(n = 208)

4.5 ± 5.4, 3.0

(n = 198)

5.4 ± 5.7, 3.0

(n = 125)

6.5 ± 6.2, 5.0^a

(n = 106)

(6.2 ± 7.0, 4.5)

(n = 20)

4.2 ± 4.6, 3.0

(n = 286)

4.1 ± 5.0, 3.0

 MG-QOL-15

 (n = 923)

8.1 ± 9.0, 5.0^a

(n = 208)

14.7 ± 13.6, 11.0

(n = 198)

16.2 ± 13.7, 13.5^a

(n = 125)

14.6 ± 12.6, 12.0

(n = 106)

(11.6 ± 8.8, 11.0)

(n = 20)

14.1 ± 13.9, 9.0

(n = 286)

13.2 ± 13.0, 9.0